Galith Kalmi, Yann Nguyen, Stephanie Amarger, Magali Aubineau, Beatrice Bibes, Claire Blanchard-Delaunay, Isabelle Boccon-Gibod, Laurence Bouillet, Paul Coppo, Marie-Caroline Dalmas, Sophie Debord-Peguet, Federica Defendi, Claire Demoreuil, Aurélie Du-Thanh, Stephane Gayet, Jerôme Hadjadj, Pierre-Yves Jeandel, David Launay, Kim Heang Ly, Chloé Mc Avoy, Mathilde Niault, Yann Ollivier, Fabien Pelletier, Marc Porneuf, Damien Roos-Weil, Olivier Fain, Delphine Gobert
BACKGROUND: Angioedema (AE) due to acquired C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is related to excessive consumption of C1-INH or to anti-C1-INH antibodies (Ab), and is frequently associated with lymphoproliferative syndromes or monoclonal gammopathies. Standard of care for prophylactic treatment in this condition is not established. Rituximab may be effective to prevent attacks, especially if the lymphoid hemopathy is controlled, but data are scarce. OBJECTIVE: to evaluate efficacy of rituximab in angioedema with acquired C1 inhibitor deficiency...
October 14, 2023: Journal of Allergy and Clinical Immunology in Practice